

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C08L 5/00, G01N 30/00, B01D 15/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/12618</b> <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)
<b>(21) International Application Number:</b> PCT/SE99/01484 <b>(22) International Filing Date:</b> 27 August 1999 (27.08.99)  <b>(30) Priority Data:</b> 9802882-2 28 August 1998 (28.08.98) SE  <b>(71) Applicant (for all designated States except US):</b> AMERSHAM PHARMACIA BIOTECH AB [SE/SE]; Björkgatan 30, S-751 84 Uppsala (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LARSSON, Per-Olof [SE/SE]; Fågelhundsvägen 56, S-226 53 Lund (SE). GUSTAVSSON, Per-Erik [SE/SE]; Vikingavägen 11B, S-224 76 Lund (SE).  <b>(74) Agents:</b> ROLLINS, Anthony, J. et al.; Nycomed Amersham plc, White Lion Road, Amersham, Bucks HP7 9LL (GB).	<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> COMPOSITE MATERIAL AND ITS USE  <b>(57) Abstract</b>  Composite material which is characterized in that it comprises two or more components of which one is super-porous polysaccharide (main component) and the other component(s) (secondary component(s)) are different from the main component with exception of the case that the composite contains an electrically conducting monolithic secondary component which is intended to be, or is, connected between two electrodes. The use of the super-porous polysaccharide material according to the above in separations, the growing of cells, chemical synthesis, enzymatic/catalytic reactions.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

1  
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01484

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C08L 5/00, G01N 30/00, B01D 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C08L, G01N, B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 9319115 A1 (PHARMACIA LKB BIOTECHNOLOGY AB), 30 Sept 1993 (30.09.93)  --	1-2,4,6-10, 12-13
Y	File WPI, Derwent accession no. 95-158047, Mitsubishi Kasei Corp: "Composite adsorbent used for carrier of liquid chromatography - where capacity of ion exchange, and satd. adsorption of albumin are specific values"; JP,A,7080294, 950328, DW9521  --	1-2,4,6-10, 12-13
A	US 4169804 A (ANTHONY F. YAPPEL, JR.), 2 October 1979 (02.10.79), column 1, line 66 - column 2, line 2; page 2; column 4, line 30 - line 33, column 4, line 53 - column 5, line 43  --	1-13

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 1999

Date of mailing of the international search report

21 -12- 1999

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Helena Danielsson/EÖ

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01484

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Talanta, Volume 45, No 3, January 1998, Masoud Khayyami et al, "Development of an amperometric biosensor based on acetylcholine esterase covalently bound to a new support material" page 557 - page 563</p> <p style="text-align: center;">-- -----</p>	1-13

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 99/01484


Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9319115 A1	30/09/93	AT 181087 T	15/06/99
		AU 3772693 A	21/10/93
		CA 2132344 A	30/09/93
		DE 69325266 D	00/00/00
		EP 0615569 A	21/09/94
		EP 0631597 A,B	04/01/95
		FI 942493 A	27/05/94
		JP 7505415 T	15/06/95
		NO 179339 B,C	10/06/96
		NO 941979 A	27/05/94
		SE 9200827 D	00/00/00
		US 5723601 A	03/03/98
US 4169804 A	02/10/79	NONE	

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

ROLLINS, Anthony J.  
NYCOMED AMERSHAM PLC  
White Lion Road  
Amersham, Bucks HP7 9LL  
GRANDE BRETAGNE



## PCT

### NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing (day/month/year)	30.10.2000
-------------------------------------	------------

Applicant's or agent's file reference PL 9824 PCT	<b>IMPORTANT NOTIFICATION</b>
------------------------------------------------------	-------------------------------

International application No. PCT/SE99/01484	International filing date (day/month/year) 27/08/1999	Priority date (day/month/year) 28/08/1998
-------------------------------------------------	----------------------------------------------------------	----------------------------------------------

Applicant AMERSHAM PHARMACIA BIOTECH AB et al.
---------------------------------------------------

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
---------------------------------------	--------------------



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Aperribay, I

Tel. +49 89 2399-8154



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PL 9824 PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE99/01484	International filing date (day/month/year) 27/08/1999	Priority date (day/month/year) 28/08/1998
International Patent Classification (IPC) or national classification and IPC C08L5/00		
Applicant AMERSHAM PHARMACIA BIOTECH AB et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  27/03/2000	Date of completion of this report  30.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Kairi, M  Telephone No. +49 89 2399 8672 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/SE99/01484

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-11 as originally filed

**Claims, No.:**

1-13 as received on 11/10/2000 with letter of 03/10/2000

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N) Yes: Claims 1-13  
No: Claims

Inventive step (IS) Yes: Claims  
No: Claims 1-13

Industrial applicability (IA) Yes: Claims 1-13  
No: Claims



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/SE99/01484

---

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**Disclaimer.**

It is assumed that the disclaimer is intended to delimit the present claimed subject-matter from the document "Talanta, Volume 45, No. 3, January 1998" (D4). In that case the disclaimer is too broad. A disclaimer introduced in order to establish novelty should exclude only the subject-matter which is disclosed in the state of the art. D4 discloses a composite material comprising reticulated vitreous carbon (RVC) and superporous agarose.

**Article 33(2) PCT**

The subject-matter of Claim 1 is distinguished from D4 through the disclaimer. None of the remaining prior art discloses a composite material comprising a super-porous polysaccharide (main component) and at least one other component (secondary component) which is different from the main component.

**Article 33(3) PCT**

Closest prior art: D4

Document D4 discloses a composite material consisting of reticulated vitreous carbon (RVC) and superporous agarose which is used to prepare a flow-through working electrode (page 561-page 562, point 3.3). A biosensor was prepared based on enzyme coated RVC-superporous agarose. The superporous agarose integrated in the RVC structure may be prepared as discrete particles for chromatographic use or as a continuous beds in a number of physical shapes. The subject-matter of the present application is distinguished from D4 through the disclaimer.

The object of the present invention is to produce a modified super-porous polysaccharide material which has desired matrix characteristics, such as physical stability (pressure resistance), separation characteristic with respect to discriminating between substances with different molecular weights and geometric shape, stability of the linked affinity ligands and various density values.

The solution offered (combining the super-porous polysaccharide with at least

one other component) is obvious in view of the fact that D4 discloses such a combination of a super-porous polysaccharide with another component further containing an affinity ligand.

Closest prior art: WO-A-9319115 (D1)

The document D1 discloses polysaccharide gels which have besides pores of molecular dimension also interconnected continuous macropores with a pore diameter in the range of from 0.5 to 1000 micrometers to be used as high performance chromatographic gels (page 2, paragraph 2 to page 3, paragraph 2; page 4, paragraph 4).

The document "File WPI, Derwent accession no. 95-158047" (D2) discloses a composite absorbent (A) having ion exchanging function comprising: (A1) a porous material of chitosan of which fine pores support (A2) a cross-linked gel of hydrophilic polymer. The adsorbent has a large adsorbing power and high mechanical strength, driven from inserting the cross-linked gel having poor strength into pores of the porous material of chitosan and is superior in liquid permeation and slight amount of volume varying.

The subject-matter of the present application differs from D1 in that the super-porous polysaccharide is combined with at least one other component which gives the composite material specific functional characteristics.

The object of the present invention is to provide a super-porous polysaccharide material having specific functional characteristics.

The solution provided is obvious, since the skilled man starting from D1 and in view of D2 would have obviously considered a composite material resulting from combining the super-porous polysaccharide of D1 with another component which is able to give the composite material specific functional characteristics.

On the basis of the above no inventive step can be recognized for the subject-matter of Claim 1 of the present application.

The individual feature of D2 is disclosed in D1 (page 6, paragraph 3) and in D4 (page 561, point 3.3, paragraph 2).

The individual features of Claims 3-5 are disclosed in D2.

The individual features of Claims 6-10 are disclosed in D1 (page 2, paragraph 4; Examples 10, 11 and 14) and D4 (page 561 to page 562, point 3.3).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/SE99/01484

The individual feature of Claim 11 is disclosed in D4 (page 558, point 2.1. "Chemicals", last sentence and page 560, point 3.2.1. "RVC electrodes", first sentence).

The individual features of Claim 12 are disclosed in D1 (page 7, paragraph 4 to page 8, paragraph 5) (superporous spherical particles, superporous fibers, superporous continuous beds, superporous membranes) and D4 (page 561, point 3.3, paragraph 2).

The features of Claim 13 are disclosed in D1 (page 1, paragraph 1; page 4, paragraphs 1 and 3; Examples 10, 11 and 14) and D4 (pages 561 and 562, points 3.3 and 3.4).

On the basis of the above no inventive step can be recognized for the subject-matter of Claims 2-13 of the present application.

**Re Item VIII**

**Certain observations on the international application**

The term "super-porous" in Claim 1 is unclear (Article 6 PCT).

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PL 9824 PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE99/01484	International filing date (day/month/year) 27/08/1999	Priority date (day/month/year) 28/08/1998
International Patent Classification (IPC) or national classification and IPC C08L5/00		
Applicant AMERSHAM PHARMACIA BIOTECH AB et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  27/03/2000	Date of completion of this report  30.10.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Kairi, M  Telephone No. +49 89 2399 8672 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/SE99/01484

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-11 as originally filed

**Claims, No.:**

1-13 as received on 11/10/2000 with letter of 03/10/2000

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims 1-13
	No:	Claims
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-13
Industrial applicability (IA)	Yes:	Claims 1-13
	No:	Claims

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/SE99/01484

---

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**Disclaimer.**

It is assumed that the disclaimer is intended to delimit the present claimed subject-matter from the document "Talanta, Volume 45, No. 3, January 1998" (D4). In that case the disclaimer is too broad. A disclaimer introduced in order to establish novelty should exclude only the subject-matter which is disclosed in the state of the art. D4 discloses a composite material comprising reticulated vitreous carbon (RVC) and superporous agarose.

**Article 33(2) PCT**

The subject-matter of Claim 1 is distinguished from D4 through the disclaimer. None of the remaining prior art discloses a composite material comprising a super-porous polysaccharide (main component) and at least one other component (secondary component) which is different from the main component.

**Article 33(3) PCT**

Closest prior art: D4

Document D4 discloses a composite material consisting of reticulated vitreous carbon (RVC) and superporous agarose which is used to prepare a flow-through working electrode (page 561-page 562, point 3.3). A biosensor was prepared based on enzyme coated RVC-superporous agarose. The superporous agarose integrated in the RVC structure may be prepared as discrete particles for chromatographic use or as a continuous beds in a number of physical shapes. The subject-matter of the present application is distinguished from D4 through the disclaimer.

The object of the present invention is to produce a modified super-porous polysaccharide material which has desired matrix characteristics, such as physical stability (pressure resistance), separation characteristic with respect to discriminating between substances with different molecular weights and geometric shape, stability of the linked affinity ligands and various density values.

The solution offered (combining the super-porous polysaccharide with at least



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/SE99/01484

one other component) is obvious in view of the fact that D4 discloses such a combination of a super-porous polysaccharide with another component further containing an affinity ligand.

Closest prior art: WO-A-9319115 (D1)

The document D1 discloses polysaccharide gels which have besides pores of molecular dimension also interconnected continuous macropores with a pore diameter in the range of from 0.5 to 1000 micrometers to be used as high performance chromatographic gels (page 2, paragraph 2 to page 3, paragraph 2; page 4, paragraph 4).

The document "File WPI, Derwent accession no. 95-158047" (D2) discloses a composite absorbent (A) having ion exchanging function comprising: (A1) a porous material of chitosan of which fine pores support (A2) a cross-linked gel of hydrophilic polymer. The adsorbent has a large adsorbing power and high mechanical strength, driven from inserting the cross-linked gel having poor strength into pores of the porous material of chitosan and is superior in liquid permeation and slight amount of volume varying.

The subject-matter of the present application differs from D1 in that the super-porous polysaccharide is combined with at least one other component which gives the composite material specific functional characteristics.

The object of the present invention is to provide a super-porous polysaccharide material having specific functional characteristics.

The solution provided is obvious, since the skilled man starting from D1 and in view of D2 would have obviously considered a composite material resulting from combining the super-porous polysaccharide of D1 with another component which is able to give the composite material specific functional characteristics.

On the basis of the above no inventive step can be recognized for the subject-matter of Claim 1 of the present application.

The individual feature of D2 is disclosed in D1 (page 6, paragraph 3) and in D4 (page 561, point 3.3, paragraph 2).

The individual features of Claims 3-5 are disclosed in D2.

The individual features of Claims 6-10 are disclosed in D1 (page 2, paragraph 4; Examples 10, 11 and 14) and D4 (page 561 to page 562, point 3.3).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/SE99/01484

The individual feature of Claim 11 is disclosed in D4 (page 558, point 2.1. "Chemicals", last sentence and page 560, point 3.2.1. "RVC electrodes", first sentence).

The individual features of Claim 12 are disclosed in D1 (page 7, paragraph 4 to page 8, paragraph 5) (superporous spherical particles, superporous fibers, superporous continuous beds, superporous membranes) and D4 (page 561, point 3.3, paragraph 2).

The features of Claim 13 are disclosed in D1 (page 1, paragraph 1; page 4, paragraphs 1 and 3; Examples 10, 11 and 14) and D4 (pages 561 and 562, points 3.3 and 3.4).

On the basis of the above no inventive step can be recognized for the subject-matter of Claims 2-13 of the present application.

**Re Item VIII**

**Certain observations on the international application**

The term "super-porous" in Claim 1 is unclear (Article 6 PCT).

with coloured amendments

12

### CLAIMS

1. Composite material, characterized in that it comprises two or more components of which one is super-porous polysaccharide (main component) which outside the superpores  
5 contains a gel phase with micro-pores and the other component(s) (secondary component(s)) are different from the main component with exception of the case that the composite contains an electrically monolithic secondary component which is intended to be, or is, connected between two electrodes.
- 10 2. Composite material according to claim 1, characterized in that the main component is in the shape of discrete particles or a continuous structure.
3. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is outside the super-pores but inside the main component's gel  
15 phase.
4. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is in the super-pores of the main components.
- 20 5. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is ~~found~~present in both the super-pores and in the gel phase of the main component.
6. Composite according to any of claims 1-5, characterized in that it has at least one  
25 affinity ligand.
7. Composite material according to claim 6, characterized in that the respective affinity ligand is linked to the main component and/or to one or more secondary components.
- 30 8. Composite material according to claim 6, characterized in that at least one of the affinity ligands is linked to the main component.
9. Composite material according to claim 6, characterized in that at least one of the affinity ligands is connected to one of the secondary components.

35

with coloured amendments

13

10. Composite material according to any of claims 6-9, characterized in that said at least one of the affinity ligands is an ion exchange group, amphoteric group, chelating group, bioaffine group, a group which can be used in covalent chromatography, a group which gives  $\pi$ - $\pi$ -interaction, a group which can be used during hydrophobic interactions chromatography, a group which give thiophilic interactions, or an affinity binding inorganic material which is a secondary component, such as hydroxyapatite, etc.
11. Composite material according to any of claims 1-10, characterized in that the secondary components are porous with average pore diameters which are greater than the average pore diameters in the gel phase of the main component.
12. Composite material according to any of claims 1-11, characterized in that it is in the shape of fibres, beads, or a monolith, such as a membrane or a bed.
13. The use of the composite material according to any of claims 1-11 in separations, the culturing of cells, chemical synthesis, enzymatic/catalytic reactions.

Composite material and its use

## Field of the invention

- 5 The invention relates to a composite material in which is comprised super-porous polysaccharide material of the type which has been previously described in WO-A-9319115 (US-A-5,723,601).

Porous polysaccharide material contains two types of pores. Partly pores with a small  
10 diameter (often less than 0.05 micrometers, micro-pores) where mass transportation occurs by diffusion when a liquid is transported through the material. Partly large pores - super-pores - in which mass transportation can take place through a convective flow when the pores are open. The part of the material that lies outside the super-pores is called the gel phase and consequently contains the micro-pores.

15

We have described super-porous agarose matrices in a series of articles. See Gustavsson et al., J. Chromatog. A 734 (1996) 231-240, Gustavsson et al., J. Chromatog. A 776 (1997) 197-203, Gustavsson et al., J. Chromatog. A 795 (1998) 199-210.

- 20 It is known in the prior art to place super-porous agarose in the pores of highly porous electrically conductive material (reticulated vitreous carbon, RVC) in order to increase the material's capacity to carry affinity-bonding ligands. See Khayyami, Thesis "Biosensors and chromatographic supports based on new combinations of conductive material", Lund University, Lund (1996). Their fields of use have been as biosensors or as chromatography  
25 adsorbents that should be able to be electroeluted. Agarose alone is unusable in the current type of biosensors and for electroelution. By electroelution is meant that a bonding ligand is oxidised/reduced in an electrochemical way to be non-bonding so that elution is made possible.
- 30 Unfortunately it has not yet been possible to completely use super-porous polysaccharide material in the way that would be desirable. Consequently one often wishes that the matrices characteristics would be better with respect to physical stability (pressure resistance), separation characteristics with respect to discriminating between substances with different molecular weights and geometric shape, stability of the affinity ligands which are linked to a  
35 super-porous matrix etc. It can especially be mentioned that certain applications, especially those that require matrices in particular shapes, require a density that more or less strongly deviates from 1 g/cm<sup>3</sup>.

Previous publications, such as WO-A-9319115 (US-A-5,723,601), have been relatively scarce about deficiencies of super-porous polysaccharide material and how to overcome these deficiencies. To our knowledge previous publications, such as WPI/Derwent AN 95-158047  
5 relating to composite polysaccharide material do not discuss the presence of super-pores therein.

We have now discovered that it is very easy to manufacture composite materials in which a super-porous polysaccharide matrix is included as the main component of the material and  
10 that this can offer advantages with respect to the above-mentioned deficiencies of prior art super-porous polysaccharides.

### **The invention**

15 A first aspect of the invention is a composite material that comprises two or more components. The composite is characterised in that one of the component is a super-porous polysaccharide material (main component). Other components are called secondary components (secondary components 1, 2, 3 etc). That the composite material of the invention contains an electrically conducting monolithic secondary component which is intended to  
20 connect or which is connected between two electrodes is not part of this aspect of the invention.

Another aspect of the invention is the use of the composite during separation, cell culturing, chemical synthesis on solid phase, and the performance of enzymatic/catalytic reactions  
25 where the enzyme is linked to the composite material in accordance with the invention (the method aspect of the invention).

The composite material can be in the form of fibres, balls (beads, particles), or a monolith. As an example of a monolith can be mentioned membranes or a cast continuous chromatographic  
30 bed. With matrices in the shape of balls one often speaks of sizes in the intervals of 0.1-1000  $\mu\text{m}$ , such as 1-1000  $\mu\text{m}$  or 5-500 $\mu\text{m}$ .

### **The main component (super-porous polysaccharide material)**

35 Typically super-porous polysaccharide materials are often manufactured starting from agar, agarose, alginate, dextran, carageenan, chitosan, cellulose or starch. Which material is chosen in the actual case is often determined by the characteristics that one wishes that the final

product shall have with respect to pore size, charge, stability in different media, cost etc. The super-porous polysaccharide material may be a homogeneous mixture of different polysaccharides forming the gel phase of the material. Super-porous polysaccharide material for use in the invention can be made in the same way as stated in WO-A-9319115.

5

The term super-pores means that a flow which can give convective mass transport should be able to be applied through the pores. This means as a rule that there shall be pores with diameters which are in the interval of 0.5-1000  $\mu\text{m}$ , with a preferred interval of between 1-1000  $\mu\text{m}$ . For matrices in the shape of particles which are packed to form a bed there is  
10 furthermore a condition that the relationship between super-pore diameter and the particle diameter is in the interval of 0.01-0.3, with a preference for 0.05-0.2.

The amount of the main component in the composite material of the invention can vary within extremely wide limits. Based on dry weight the amount of main component can consequently  
15 vary from just over 0% to just under 100%, such as 0.01-99.99% (w/w). Based on volume and measured on composite material saturated with water the main component can form 5-99.99%, for example 50-99% (v/v).

### Secondary components

20

The secondary components of the composite material can be a) particles which are enveloped in the main components gel phase and/or in the super-pores, or b) a continuous phase in the super-pores, or c) polymer chains which are homogeneously mixed in the gel phase with the main component's polysaccharide. In the variant a) there are particles which are coated with  
25 super-porous polysaccharide material. In the variant b) there is a macro-porous secondary component completely surrounding the super-porous polysaccharide material.

The secondary components differ from the main components with respect to at least one characteristic. The secondary components can be selected from different organic and  
30 inorganic material. They can be polymers with a completely synthetic origin or be based on so-called biopolymers, for example polysaccharides of the same or different types than those that are current as the main component. They can be derivituted to carry different groups that can be used during the use of the composite material of the invention. In the composite material of the invention a secondary component can be present as a solid substance or fluid  
35 and is as a rule insoluble in water (in the absence of additives that change its solubility).

A secondary component can be porous. If a secondary component is porous then its average pore diameter (in the composite material) can be larger than or smaller than or the same as the average pore diameter of the micro-pores in the main component's gel phase.

- 5 The secondary components can have a density that more or less greatly differs from  $1 \text{ g/cm}^3$ .

As examples of the great variability which applies to the secondary components reference can be made to WO-A-9200799. One can also mention the following functions that can be introduced into the composite via a secondary component:

10

- density, for example particles with high or low density.
- magnetic attraction, for example particles of magnetite.
- affinity functions, described more closely in the following section.
- mechanical stability, for example polymers, particles or continuous structures such as

15

- reticulated vitreous carbon (RVC).
- thermal stability, for example polymers or other reagents which stabilise the melting point of main component 1.
- photo-chemical stability, for example the addition of coloured particles.
- microbial stability, for example polymers which prevent the entry of micro-

20

- organisms/hydrolytic enzymes.
- electrical conductivity, for example electrically conductive polymers, in particulate or monolithic form. Particularly the case that an electrically conducting secondary component is monolithic and connected between two electrodes is not included in the composite in accordance with the invention.

25

- pore size modification, for example polymer networks which reduce the size of the super-pores in the main component.
- Heat conductivity, for example particles or heat conducting structures such as reticulated vitreous carbon, which can rapidly remove or add heat.
- Variable composite material characteristics, for example via so-called smart polymers.

30

Smart polymers are polymers which dramatically can change their characteristics as a result of an outside stimulus. An example is to introduce a thermo-responsive smart polymer into the super-pores and thereby make these variably permeable via small temperature changes.

35 **Derivitated forms of the composite material of the invention**



The composite material of the invention can be provided with so called affinity ligands which are bonded to the main components and/or to one or more of the secondary components of the composite material. As examples of affinity ligands can be mentioned anion- or cation exchange groups, amphiphilic groups, chelating groups, bio-affine groups, groups which can  
5 be used in covalent chromatography, groups which give  $\pi$ - $\pi$ -interaction, groups which can be used during hydrophobic interaction chromatography, groups which give thiophilic interactions etc. A special kind is affinity ligands are present on affinity bonding inorganic material for example hydroxyapatite, etc.

- 10 The different components in the composite material of the invention can, when they are based on polymers, be cross-linked in a way that is in itself known.

Cross-linking and the introduction of affinity ligands can take place in the finished composite material or in the respective main component before the composite material is made.

15

It is evident above that the cross-linking structures, the introduced ligands and other binding structures which occur through chemical derivatisation of a base material are not called secondary components in connection with the invention.

## 20 **Manufacturing of the composite material of the invention**

The composite material in accordance with the invention can be made through first making a solution of the polysaccharide which is to be the main component in the finished composite material and suspending particles of the secondary components 1, 2, 3 etc. in the solution and  
25 thereafter proceeding as is known from the manufacturing of super-porous polysaccharide material in accordance with WO-A-9319115. It is essential to make sure that the secondary components 1, 2, 3 etc. do not sediment out during the manufacturing process.

A composite in accordance with the invention can even be manufactured through a) starting  
30 from super-porous polysaccharide material (the main component) manufactured in accordance with WO-A-9319115 and introducing secondary components 1, 2, 3 etc. into the super-pores, or b) starting from a macro-porous secondary component and manufacturing the super-porous polysaccharide material (main component) in the pores of the macro-porous secondary component.

35

## **The field of use of the invention**

The composite material in accordance with the invention has potentially the same area of use as other previously known porous materials. Some actual areas are, amongst others, in connection with separations, cell-culturing, bio-reactors and chemical synthesis. Examples of actual bio-reactors are, amongst others, enzyme reactors and other reactors where the catalyst  
5 is bound to a matrix. Examples of actual chemical syntheses are the synthesis of polymer in the solid phase, such as oligopeptides and oligonucleotides. During cell culturing the cells can be grown on the composite material of the invention.

By separation is meant first of all separations based on the affinity between the substance  
10 which is to be separated and a structure (ligand) on the matrix of the invention or based on differences in geometric shape and molecular weight between different substances. These separations can take place in the form of chromatographic or stepwise methods or methods which are based upon membrane technology. According to the first variation a solution containing the substances which are to be separated from each other is passed through a bed  
15 which contains the composite material of the invention. The bed can be in the shape of a porous monolithic matrix, packed particles or a so-called expanded bed (see WO-A-9218237). During stepwise methods the composite material of the invention is in the shape of particles which are suspended in a solution which contains the substances which are to be separated from each other. Elution/desorption/freeing of the bonded substances can then, amongst  
20 others, take place through the addition of solutions that interrupt the bonds between the ligand and the bonded substance. Depending on the type of ligand the solution can contain desorbing agents that give an increased ion strength, a changed pH or which directly compete with the bonding between the ligand and the bonded substance. Electroelution which uses a composite material with a monolithic electrically conducting secondary-component which is connected  
25 between two electrodes in combination with electroelution is not included in the method aspect of the invention.

In principle, beds constructed in a similar way can be used during cell-culture, chemical synthesis and in bio-reactors.

30 The invention is defined furthermore by the accompanying claims and will now be illustrated with a number of non-limiting examples.

#### EXPERIMENTAL PART

35 In this experiment we have started from the examples which were given in the International Patent Application WO-A-9319115.

**Example 1. Monolithic composite material. Continuous super-porous membrane with filler in the gel-phase.**

- 5 • 10 ml of a 6% agarose solution was made in accordance with example 1 in WO-A-9319115 (solution A).
- 10 ml cyclohexane + 1 ml Tween-80 manufactured in accordance with example 1 in WO-A-9319115 (solution B)
- 10 ml filler was heated to 60°C (solution C).

10

Solution A and solution C were combined while being stirred at 60°C. Thereafter solution B was added while being stirred (1000 rpm) at 60°C in order to obtain emulsion 1 in the same way as described in WO-A-9319115. From emulsion 1 super-porous continuous composite membranes were made in accordance with example 4 in WO-A-9319115.

15

The following alternative filler was used:

- a. Anion exchanger, AG 1X-8 minus 400 mesh (Bio-Rad Laboratories, U.S.A.). The resulting composite material was shown to function through the determination of break-through curves for ATP.
- 20 b. Silica material LiChroprep Si 100, 40-63  $\mu\text{m}$  (E. Merck Darmstadt, Germany).
- c. Agarose spheres (6% Agarose 25-75  $\mu\text{m}$ ) derivatised with Cibacron-blue. These agarose spheres were manufactured in accordance with Gustavsson and Larsson, J. Chromatography A, 734 (1996) 231-240, but with a stirring speed of 1500 rpm.
- d. Graphite, powder synthetic, 1-2  $\mu\text{m}$  (Aldrich, U.S.A.). In this case 20 ml of 6% agarose
- 25 solution and 2.5 ml of graphite powder were used.

**Example 2. Composite material in the shape of spheres/beads. Super-porous agarose beads having super-pores in which a low percentage agarose solution was cast.**

- 30 The following super-porous agarose spheres were manufactured in accordance with WO-A-9319115 using as starting material:
1. Agarose content 6%, particle sizes 300-500  $\mu\text{m}$ , super-pore volume 40%, super-pore diameter 30  $\mu\text{m}$ .
2. Agarose content 6%, particle sizes 106-180  $\mu\text{m}$ , super-pore volume 40%, super-pore
- 35 diameter 30  $\mu\text{m}$ .

These super-porous agarose spheres were used in order to manufacture composite material through filling the super-pores with 0.5% agarose in accordance with the following:

- The interstitial water of 20 ml sedimented super-porous agarose beads was filtrated off in a Büchner filter and the super porous agarose beads transferred to an E-flask. The E-flask was heated to 50°C in a thermostat controlled water bath (gel A).
- 0.5 g agarose (low gelling temperature, Sigma A-4018) was added to 100 ml distilled water and heated to 95-100°C in a microwave oven. The agarose solution was tempered down to 50°C in a thermostat controlled water bath (solution B).
- Solution B was added to gel A and placed in a vibrating water bath (50°C) for 22 hours (suspension C).
- 200 ml of cyclohexane + 5.6 g Span-85 (Fluka, Buchs, Switzerland) were tempered to 50°C in a stirred tank reactor. Suspension C was added to the tank reactor (50°C) while being stirred (1500 rpm). After 1 minute the temperature in the tank reactor was lowered to 5°C with continued stirring (1500 rpm).

In the final stage the desired composite material was formed, that is to say super-porous agarose beads with 0.5% agarose in the super-pores and normal agarose beads with an agarose content of 0.5%. The latter could be easily separated through sedimentation.

#### **Functional testing of the agarose composite beads (6% - 0.5% agarose):**

The above manufactured composite beads were packed in chromatography columns and used for gel filtering. These composite beads could separate latex particles (0.5 µm) and Blue Dextran MW 2 000 000, which were eluted at the same time during gel filtering experiments with columns packed with normal agarose beads or super-porous agarose beads. The explanation is that Blue Dextran 2 000 000 has access to the super-pore volume while the latex particles does not have access to the volume because they are excluded from 0.5% agarose pores. This type of composite bead can be used for increasing the separation area for DNA during gel filtration.

#### **Example 3. Composite material in the shape of beads. Super-porous agarose/polyacrylamide beads.**

**Comment.** In this composite the gel phase itself consist of cross-linked polyacrylamide + agarose.

- 0.0625 g N,N'-methylene-bis-acrylamide was dissolved in 25 ml 10% acrylamide. The solution was vacuum-degassed and tempered to 60°C (solution A).
- 2.4 g agarose was dissolved in 30 ml vacuum-degassed water and heated in a microwave oven to 95-100°C. The agarose solution was tempered to 60°C in a stirred tank reactor (solution B).
- 25 ml cyclohexane with 1.5 ml Tween-80 was degassed with nitrogen and tempered to 60°C (solution C).
- 150 ml cyclohexane with 8.4 g Span 85 was degassed with nitrogen and tempered to 60°C (solution D).

10

The solution A was mixed into the solution B while being stirred (500 rpm, 15 min) at 60°C (solution E). 0.05 ml TEMED and 30 mg ammonium persulphate was separately dissolved in a small quantity of degassed water and added to the solution E while being stirred (500 rpm, 2 min). The solution C was added to the solution E and emulsified at 100 rpm for 0.5 min. The solution D was added to solution E and emulsified at 500 rpm for 1 minute, thereafter being cooled to 25°C. Stirring continued for 30 minutes at 500 rpm.

15

The gel beads obtained were washed as described in WO-A-9319115.

**20 Example 4. Monolithic composite material based on a monolithic mechanical support matrix and super-porous polysaccharide matrices.**

Reticulated vitreous carbon was used (RVC; Duocell, Energy Research and Generation, Oakland, CA, USA) as a mechanical support matrix.

25

The emulsion 1 in accordance with example 1 in WO-A-9319115 was placed in a thermostat controlled glass column (50°C) in which a matrix of RVC was placed. The column was lowered into a cooling bath wherein the agarose phase solidified. The resulting composite material was trimmed at its ends and washed free from organic solvent. The function of the material was tested in comparative chromatographic studies with BSA as the chromatographed molecule.

30

**Example 5. Monolithic composite material based on super-porous agarose and yeast cells.**

35

A composite was manufactured in accordance with example 1. 10 ml of 50% content yeast suspension (bakers yeast) was used as a secondary component. The finished composite was investigated and found to have enzymatic activity (alcohol dehydrogenase activity).

**5 Example 6. Composite material in the shape of beads. Ion-exchange matrix.**

- 10 ml 2-6% agarose solution was made (60°C). To the solution was added a sodium alginate solution (4% w/v) to a final concentration of 0.25-1% (w/v) (solution A).
- 10 ml cyclohexane + 0.6 ml Tween-80 were heated to 60°C (solution B).
- 10 • 50 ml cyclohexane + 2 g Span 85 were heated to 60°C (solution C).
- The solution B was added to solution A and stirred at 1000 rpm for 2 minutes at 60°C (solution D).

Super-porous alginate-agarose beads were manufactured in accordance with the following two methods:

- 15 Method 1: Solution D was added to solution C in a stirred reactor tank (600 rpm, 60°C). The agarose was allowed to solidify after 1 minute by cooling the reactor tank to 25°C. The alginate in the agarose phase was polymerised through a  $\text{CaCl}_2$ -water solution (small volume) being added to the reactor and while being stirred just before or just after the cooling.

20

- Method 2: The solution D was added drop-wise with a Pasteur pipette down in a heated beaker (60°C). The beaker contained two phases. The top phase consisted of solution C. The bottom phase consisted of 1.5%  $\text{CaCl}_2$  in water. The beaker was stirred with a magnetic stirrer without the phases being mixed. The composite material made was washed with water, ethanol-water (1:1) and water.

25

**Example 7. Monolithic agarose-hydroxyl apatite composite material.**

- 25 ml sedimented hydroxyl apatite in 1 mM sodium phosphate buffer went through a series of sedimentations under which the smallest particles (in total 9 ml of the sedimented hydroxyl apatite) were removed. 5 ml sedimented volume of the hydroxyl apatite which was left (1mM sodium phosphate buffer pH 6.8) was heated with a thermostat control to 60°C. 20 ml of an agarose solution (8% w/v) was made through heating for one minute a suspension of agarose in water to 95-100°C in a microwave oven. During the heating the agarose powder was maintained well suspended through occasional shaking. The agarose solution was heated to 60°C using a thermostat control whereafter 15 ml was added to the thermostat temperature-controlled hydroxyl apatite. The solution with the agarose-hydroxyl apatite was stirred then at

35

1000 revolutions per minute in a thermostat controlled water bath (60°C). After 5 minutes a mixture of 0.75 ml Tween-80 and 10 ml cyclohexane (60°C was added). The mixture was emulsified through stirring at 1000 revolutions per minute for two minutes. The emulsion was poured into glass columns (16 mm inside diameter) which were held at a thermostat

5 controlled temperature of 60°C in a water bath. After 30 seconds the glass columns were transferred to an ice-bath in order to be cooled. The insoluble continuous beds (containing hydroxyl apatite) which were obtained were trimmed to a length of 1.4 cm and placed in glass columns (16 mm ID) which were equipped with flow adapters. The organic phase in the super-pores was removed through pumping sodium phosphate buffer pH 6.8, ethanol-1 mM

10 sodium phosphate buffer pH 6.8 (50:50 v/v) and finally sodium phosphate buffer pH 6.8 through the column. The composite bed was stored at 4°C until it was used.

The columns were then connected to an HPLC-system (Amersham Pharmacia Biotech AB; Uppsala, Sweden) including pumps, injection valves, UV-Vis detector and printer. Separation

15 of three model proteins (lysozyme, cytochrome c and bovine serum albumine) were then studied with three different flow speeds (15 cm/h, 30 cm/h, 60 cm/h). The composite bed had a super-pore/interstitial porosity of 33% (defined by the method of production) and a super-pore/interstitial average pore diameter of 30 µm (measured through observation in a microscope).

## CLAIMS

1. Composite material, characterized in that it comprises two or more components of which one is super-porous polysaccharide (main component) and the other component(s)  
5 (secondary component(s)) are different from the main component with exception of the case that the composite contains an electrically monolithic secondary component which is intended to be, or is, connected between two electrodes.
2. Composite material according to claim 1, characterized in that the main component is  
10 in the shape of discrete particles or a continuous structure.
3. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is outside the super-pores but inside the main component's gel phase.  
15
4. Composite material according to any of claims 1-2, characterized in that at least one of the secondary components is in the super-pores of the main components.
5. Composite material according to any of claims 1-2, characterized in that at least one  
20 of the secondary components is found in both the super-pores and in the gel phase of the main component.
6. Composite according to any of claims 1-5, characterized in it has at least one affinity ligand.  
25
7. Composite material according to claim 6, characterized in that the respective affinity ligand is linked to the main component and/or to one or more secondary components.
8. Composite material according to claim 6, characterized in that at least one of the  
30 affinity ligands is linked to the main component.
9. Composite material according to claim 6, characterized in that at least one of the affinity ligands is connected to one of the secondary components.
- 35 10. Composite material according to any of claims 6-9, characterized in that said at least one of the affinity ligands is a ion exchange group, amphoteric group, chelating group, bio affine group, a group which can be used in covalent chromatography, a group which gives  $\pi$ -



$\pi$ -interaction, a group which can be used during hydrophobic interactions chromatography, a group which give thiophilic interactions, or an affinity binding inorganic material which is a secondary component, such as hydroxyapatite, etc.

- 5 11. Composite material according to any of claims 1-10, characterized in that the secondary components are porous with average pore diameters which are greater than the average pore diameters in the gel phase of the main component.
12. Composite material according to any of claims 1-11, characterized in that it is in the  
10 shape of fibres, beads, or a monolith, such as a membrane or a bed.
13. The use of the composite material according to any of claims 1-11 in separations, the culturing of cells, chemical synthesis, enzymatic/catalytic reactions.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01484

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C08L 5/00, G01N 30/00, B01D 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C08L, G01N, B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 9319115 A1 (PHARMACIA LKB BIOTECHNOLOGY AB), 30 Sept 1993 (30.09.93)  --	1-2,4,6-10, 12-13
Y	File WPI, Derwent accession no. 95-158047, Mitsubishi Kasei Corp: "Composite adsorbent used for carrier of liquid chromatography - where capacity of ion exchange, and satd. adsorption of albumin are specific values"; JP,A,7080294, 950328, DW9521  --	1-2,4,6-10, 12-13
A	US 4169804 A (ANTHONY F. YAPEL, JR.), 2 October 1979 (02.10.79), column 1, line 66 - column 2, line 2; page 2; column 4, line 30 - line 33, column 4, line 53 - column 5, line 43  --	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

- \* Special categories of cited documents:
- "-" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier document but published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 December 1999

21 -12- 1999

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Helena Danielsson/EÖ  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01484

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Talanta, Volume 45, No 3, January 1998, Masoud Khayyami et al, "Development of an amperometric biosensor based on acetylcholine esterase covalently bound to a new support material" page 557 - page 563</p> <p>-- -----</p>	1-13

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/SE 99/01484**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9319115 A1	30/09/93	AT 181087 T	15/06/99
		AU 3772693 A	21/10/93
		CA 2132344 A	30/09/93
		DE 69325266 D	00/00/00
		EP 0615569 A	21/09/94
		EP 0631597 A,B	04/01/95
		FI 942493 A	27/05/94
		JP 7505415 T	15/06/95
		NO 179339 B,C	10/06/96
		NO 941979 A	27/05/94
		SE 9200827 D	00/00/00
		US 5723601 A	03/03/98
<hr/>			
US 4169804 A	02/10/79	NONE	
<hr/>			